U.S. Senator Calls for CMS Probe of 12,400% Drug Price Hike

John Commins, for HealthLeaders Media , June 8, 2011

"We are committed to making Colcrys accessible to everyone who can benefit from it," Richard H. Roberts, MD, president/CEO of URL Pharma said in the February statement. "In response to feedback from patients and healthcare providers, we enhanced our Co-Pay Program to facilitate access to Colcrys."

URL Pharma reiterated its "very generous patient assistance efforts" in Tuesday's statement.

The pharmaceutical firm describes Colcrys as "the only single-ingredient colchicine product approved by the FDA, and is indicated for the prevention and treatment of gout flares and for the treatment of Familial Mediterranean Fever."

Brown's letters to URL Pharma and CMS can be viewed here and here, respectively. URL Pharma's statement may be viewed here.


John Commins is a senior editor with HealthLeaders Media.
Twitter

Comments are moderated. Please be patient.


MOST POPULAR

SPONSORED REPORTS
SPONSORED HEADLINES

SIGN UP

FREE e-Newsletters Join the Council Subscribe to HL magazine

SPONSORSHIP & ADVERTISING

100 Winners Circle Suite 300
Brentwood, TN 37027

800-727-5257

About | Advertise | Terms of Use | Privacy Policy | Reprints/Permissions | Contact
© HealthLeaders Media 2015 a division of BLR All rights reserved.